Superbug surveillance: 14,000 patients swabbed to map resistance
NCT ID NCT04937361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study monitored over 14,000 hospital patients for multidrug-resistant organisms (MDROs) by taking rectal swabs and tracking bloodstream infections. Researchers analyzed the bacteria's genetics and how they resist antibiotics, aiming to understand how resistance emerges and spreads. The study also looked at how COVID-19 infection control measures affected hospital-acquired infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help hospitals better track and control the spread of drug-resistant bacteria, improving infection prevention strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It does not test any new drug or intervention, so it cannot directly lead to a cure or therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDRO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Klinik für Infektiologie und Mikrobiologie
Lübeck, Germany